Acute effects of ACE inhibition on coronary endothelial dysfunction

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 4, 2000, Pages 361-364

  Nickenig, Georg ^a   Stäblein, Alexander ^a   Wassmann, Sven ^a   Wyen, Christoph ^a   Müller, Cornelius ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

ACE inhibitors; AT1 receptor antagonists; Coronary arteries; Endothelial function

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOQUINOLINE DERIVATIVE; LOSARTAN; QUINAPRIL; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADRENERGIC SYSTEM; ARTICLE; CORONARY ARTERY BLOOD FLOW; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; MALE; MICROCIRCULATION; MIDDLE AGED; PHYSIOLOGY; TIME; VASCULAR ENDOTHELIUM; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY CIRCULATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ISOQUINOLINES; LOSARTAN; MALE; MICROCIRCULATION; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAHYDROISOQUINOLINES; TIME FACTORS; VASODILATION; VASOMOTOR SYSTEM;

EID: 0034585095     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.067     Document Type: Article

References (20)

1. Darley-Usmar VM, McAndrew J, Patel R et al. Nitric oxide, free radicals and cell signalling in cardiovascular disease. Biochem Soc Trans 1997;25:925-9.
2. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol 1997;20:II-11-17.
3. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
4. Egashira K, Suzuki S, Hirooka Y et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 1995;25:201-6.
5. Anderson TJ, Meredith IT, Charbonneau F et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-50.
6. Cox DA, Vita JA, Treasure CB et al. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989;80:458-65.
7. Egashira K, Inou T, Hirooka Y et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91:29-37.
8. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.
9. Kuga T, Mohri M, Egashira K et al. Bradykinin-induced vasodilatation of human coronary arteries in vivo: role of nitric oxide and angiotensin converting enzyme. J Am Coll Cardiol 1997;30:108-12.
10. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991;18:S110-S115.
11. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
12. Mancini GBJ, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-65.
13. Antony I, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilatation in coronary arteries of hypertensive patients. Circulation 1996;94:3115-22.
14. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DRJ, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
15. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
16. Johnston CI, Fabris B, Yamada H et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989;7:11S-16S.
17. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998;31:349-55.
18. Carey RM, Jin X, Wang Z, Siragy HM. Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand 2000;168:65-71.
19. Tsutsumi Y, Matsubara H, Masaki H et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925-35.
20. Pizard A, Blaukat A, Muller-Esterl W, Alhenc-Gelas F, Rajerison RM. Bradykinin-induced internalization of the human B2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem 1999;274:12738-47.